Mesoblast (MSB) FDA Announcement summary

Introduction and purpose

• Ryoncil (remestemcel-L) received FDA approval as the first mesenchymal stromal cell (MSC) therapy for any indication in the U.S., specifically for children aged two months and older with steroid-refractory acute graft-versus-host disease (GVHD), a life-threatening condition with high mortality rates.

Details of approval or decision

• Ryoncil is the only FDA-approved therapy for pediatric steroid-refractory acute GVHD, including adolescents and teenagers.

• Approval was based on a single-arm, multi-center Phase 3 trial showing a 70% overall response rate by Day 28, with 89% of patients having high severity Grade C or D disease.

• The product will be launched in the coming weeks, focusing initially on 45 top U.S. transplant centers representing 77% of the potential market, and will be available at transplant centers and hospitals.

• The company has substantial inventory to meet requirements for the next couple of years and has established a streamlined supply chain.

Impact on industry and stakeholders

• Sets a benchmark as the first FDA-approved mesenchymal stromal cell product, establishing regulatory and clinical expectations for future products and providing a life-saving option for children with limited treatments.

• Demonstrates a viable commercialization path for regenerative medicine and is expected to drive strategic partnerships for larger indications.

• Approval is anticipated to increase interest from larger pharmaceutical and biotech companies in regenerative medicine.

• Company holds over 1,000 patents, ensuring commercial protection through at least 2041 in major markets.